XML 27 R11.htm IDEA: XBRL DOCUMENT
v3.26.1

Business Combinations | 12 Months Ended
--- | ---
Dec. 31, 2025
Business Combinations |
Business Combinations | 4 Business Combinations Acquisitions in 2025 The Group did not effect any business combinations in the course of 2025. Acquisitions in 2024 FEops NV On July 18, 2024, the Group executed a share purchase agreement and acquired 100% of the shares of FEops NV (“FEops”) for a total purchase consideration of K€2,985. The acquisition was realized by Materialise NV. FEops NV is a Belgian company that develops AI-driven simulation technology to improve procedure efficiency and clinical outcomes for structural heart interventions. We expect the acquisition will allow Materialise to expand our cardiovascular solutions with predictive simulation capabilities, advancing the personalized treatment of patients with heart diseases. FEops will be part of the Materialise Medical segment. The fair value of the identifiable assets and liabilities at the date of acquisition was assessed at: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Carrying | ​ | ​ | ​ | ​
​ | ​ | value at | ​ | ​ | ​ | Fair value
​ | ​ | acquisition | ​ | Fair value | ​ | at acquisition
in 000€ | ​ ​ ​ | date | ​ ​ ​ | adjustments | ​ ​ ​ | date
Assets |  | ​ |  | ​ |  | ​
Brands and trademarks |  | — |  | 122 |  | 122
Technology |  | — |  | 2,938 |  | 2,938
R&D |  | 2,753 |  | (2,753) |  | —
Plant, machinery and equipment |  | 36 |  | — |  | 36
Furniture & Vehicles |  | 2 |  | — |  | 2
Right-of-use assets |  | 36 |  | — |  | 36
Deferred tax assets |  | — |  | 77 |  | 77
Other non-current financial assets |  | 33 |  | — |  | 33
Trade receivables |  | 321 |  | — |  | 321
Other current assets |  | 616 |  | — |  | 616
Cash & cash equivalents |  | 185 |  | — |  | 185
Total Assets |  | 3,982 |  | 384 |  | 4,366
Liabilities |  | ​ |  | ​ |  | ​
Long-term borrowings & Leases |  | (191) |  | — |  | (191)
Deferred tax liability |  | — |  | (77) |  | (77)
Trade payables |  | (311) |  | — |  | (311)
Payroll-related payables |  | (525) |  | — |  | (525)
Deferred revenue |  | (232) |  | — |  | (232)
Other current liabilities |  | (22) |  | — |  | (22)
Total Liabilities |  | (1,281) |  | (77) |  | (1,358)
Total identified assets and liabilities |  | 2,701 |  | 307 |  | 3,008
Goodwill (negative goodwill) |  | ​ |  | (23) |  | (23)
Acquisition price | ​ | ​ | ​ | ​ | ​ | 2,985
​ The fair value of the identified assets and liabilities included in our consolidated financial statements at the acquisition date was K€3,008. The Group acquired 100% of voting equity interests in Feops NV for a total consideration of K€2,985. This is the fair value of the identified assets and liabilities decreased by a negative goodwill of K€23. The accounting for the business combination resulted in fair values at date of acquisition of K€122 for brands and trademarks (useful life of 5 years) and K€2,938 for technology (useful life of 7 years). The valuation technique used to measure the fair value of brands and trademarks, as well as software, was the relief-from-royalty method. The relief-from-royalty method considers the discounted estimated royalty payments that the Group would be prepared to pay to license the respective asset under a contract if it did not own the asset. Key assumptions used in the application of this valuation technique include the forecasted year-on-year growth rate of revenue, the technology royalty rate and the discount rate. A deferred tax liability was recognized of K€(77) on the adjusted fair values. The discount rate used for the valuation was set at 15.03%. The carrying value of the acquired trade and other receivables approximate their fair value due to the short term character of these instruments. The FEops revenue included in the consolidated financial statement between acquisition date of July 18, 2024 and December 31, 2024 was K€568. As integration within the Materialise Medical segment started immediately it is impracticable to disclose information on profit. There are no contingent considerations payable. Acquisitions in 2023 The Group did not effect any business combinations in the course of 2023.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for business combinations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2025-01-01 -Section Disclosures -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS03_g59-63_TI -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration